1
Clinical Trials associated with Mesenchymal Stem Cells-derived Exosomes(RIGLD) / Unknown statusPhase 2IIT Clinical Trial Phase IIa, on Amelioration of Decompensated Liver Cirrhosis With Mesenchymal Stem Cells-derived Exosomes
Decompensated liver cirrhosis (LC), a life-threatening complication of chronic liver disease, is one of the major indications for liver transplantation. Recently, mesenchymal stem cell (MSC) transfusion has been shown to lead to the regression of liver fibrosis in mice and humans. However, little is known about MSC-exosome therapy. We will evaluate the therapeutic potential of mesenchymal stem Cell-Exosomes as an alternative to cell therapy in Cirrhotic patients. This study examined the safety and efficacy of umbilical cord-derived MSC-exosomes in patients with decompensated LC.
100 Clinical Results associated with Mesenchymal Stem Cells-derived Exosomes(RIGLD)
100 Translational Medicine associated with Mesenchymal Stem Cells-derived Exosomes(RIGLD)
100 Patents (Medical) associated with Mesenchymal Stem Cells-derived Exosomes(RIGLD)
100 Deals associated with Mesenchymal Stem Cells-derived Exosomes(RIGLD)